Actelion/Celltech Zavesca
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Actelion's type I Gaucher disease therapy Zavesca (miglustat) is approved July 31 as second-line treatment to Genzyme's Cerezyme (imiglucerase) in adults for whom "enzyme replacement therapy is not an option." The firm estimates the eligible population at 200-300 patients. The product will be available to a limited number of physicians due to neuropathy concerns and pregnancy category X status. Actelion and Celltech are studying miglustat in type III Gaucher disease, Niemann-Pick type C and late onset Tay-Sachs..
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.